Earnings
Home›Earnings›Results›Revolution Medicines reports updated pancreatic cancer…
Revolution Medicines reports updated pancreatic cancer trial results
61 patients in first-line metastatic PDAC cohort received 200 mg of Rasonque plus GnP
Revolution Medicines, Inc. announced updated findings from its Phase 1/2 RMC-GI-102 study of Rasonque combined with gemcitabine and nab-paclitaxel for metastatic pancreatic adenocarcinoma. The analysis revealed a confirmed objective response rate of 60.7% and a 90.2% disease control rate. As of September 28, 2026, 61 patients received 200 mg of Rasonque plus GnP, achieving a median follow-up of 18.3 months.
The regimen delivered a median duration of response of 11.1 months and a median progression-free survival of 12.8 months. Patients also experienced a 12-month overall survival rate of 76.6%. The combination therapy maintained a safety profile consistent with prior observations for both components.